Investment

Deal of the Week: Belgian billionaires back blood test platform

As the coronavirus pandemic intensifies a group of Belgian billionaires have come together to back a revolutionary silicon-chip-based diagnostics startup, which is developing tests for pandemics like the coronavirus as well as for many other diseases. 

miDiagnostics, based in Leuven, Belgium, is making a so-called nanofluidic processor on a chip that aims to enable fast, comprehensive and cost-effective analysis of a wide range of health conditions and can be used to test for viruses in pandemic situations. 

VMF Invest, the family office of Urbain Vandeurzen, a serial entrepreneur and founder of investment firm Smile Invest, together with Benaruca, the investment office of Rudi Pauwels, a pharmaceutical billionaire who is also chairman of miDiagnostics, have committed €14 million to miDiagnostics.

It comes after early investments from Alychlo, the family office of Marc Coucke, another local pharma billionaire, and Pamica, the investment office of Michel Akkermans, a serial Belgian entrepreneur, seeded miDiagnostics.

Other early investors include a Belgian pension fund and Johns Hopkins University, which is in the headlines due to its development of its  Coronavirs Research Center and map in response to the COVID-19 pandemic. 

Subscribe

You will need a Premium Plus Subscription to access this database.

Exclusive news, analysis and research on global family enterprise and private investment offices.

Access to the most comprehensive fully interactive database on global family offices, principal investment offices, and family enterprises.

Check Deal Data, Senior Staff, and New Analysis on more than 500 family/principal investment and holding groups

Already have an account? Login

Subscribe

You need at least a Premium Subscription to read this article.

The most comprehensive information service on the global family enterprise world, featuring exclusive news, analysis, research and data on global family enterprises, family offices, and private investment offices.

Premium

£299

per year

  • Exclusive reports, analysis and commentary
  • Exclusive access to family/private investment office deal information
  • Exclusive interviews with principals and senior management of family/investment offices
SUBSCRIBE NOW

Premium+

£399

per year

  • Access to All of Premium
  • Access to all of FamilyCapital Analytics, our interactive database with more than 500 detailed profiles of family investment groups

More Info

SUBSCRIBE NOW

Already have an account? Login

You've reached the end.

Continue reading free articles by registering as a Member.
Or choose a Premium Plan.

Membership

Free

  • Exclusive reports, analysis and commentary
REGISTER NOW

Premium

£299

per year

  • Exclusive reports, analysis and commentary
  • Exclusive access to family/private investment office deal information
  • Exclusive interviews with principals and senior management of family/investment offices
SUBSCRIBE NOW

Premium+

£399

per year

  • Access to All of Premium
  • Access to all of FamilyCapital Analytics, our interactive database with more than 500 detailed profiles of family investment groups

More Info

SUBSCRIBE NOW

Already have an account? Login

Leave a Reply